 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...1718192021222324252627...7475» |
- || Avastin (bevacizumab) / Roche
Clinical, Clinical data, Journal: Clinical Outcomes And Treatment Course of Eyes with Neovascular Age-Related Macular Degeneration Following the Development of Endophthalmitis. (Pubmed Central) - Dec 16, 2021
Neovascular age-related macular degeneration became quiescent in 13.3% of eyes. Most achieved better outcomes with anti-VEGF reinitiation.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: NONPERFUSION AREA QUANTIFICATION IN BRANCH RETINAL VEIN OCCLUSION: A WIDEFIELD OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY STUDY. (Pubmed Central) - Dec 16, 2021
Using widefield OCTA, we could quantify the retinal NPA of eyes with branch retinal vein occlusion. These could serve as valid references to assess the risk of neovascular complications.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Real-world evidence: Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization. (Pubmed Central) - Dec 16, 2021
Our study correlates with previous studies showing significant BCVA gains with the use of these molecules. Similarly, all three molecules seem to provide a similar duration of effects as previous studies have shown, with a low ocular adverse event rate.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: ANGIOGRAPHIC RISK FACTORS FOR RECURRENCE OF MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION. (Pubmed Central) - Dec 16, 2021
The parafoveal VDI may adequately represent the degree of congestion associated with branch retinal vein occlusion. Particularly, the VDI in the temporal sector may be a good predictor of future retinal thickening in the corresponding parafovea and the fovea and the number of ranibizumab injections.
- | Avastin (bevacizumab) / Roche
Journal: Systemic Medication Use and the Incidence and Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). (Pubmed Central) - Dec 16, 2021
None of the systemic medications analyzed were associated with GA incidence. However, calcium channel blockers were associated with a higher growth rate of GA in the study eye.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Anti-Vascular Endothelial Growth Factor Dosing and Expected Acuity Outcome at 1 Year. (Pubmed Central) - Dec 16, 2021
There seems to be a predictable, mathematically defined relationship between dose frequency and visual acuity change at 1 year in neovascular age-related macular degeneration. The performance of current treatment efforts, as suggested by reported series and Medicare claims data, seems to be substandard.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Predictors for 2-year functional and morphological outcomes of a treat and extend regimen with ranibizumab in patients with diabetic macular edema. (Pubmed Central) - Dec 16, 2021
Ranibizumab applied in a TER without loading dose in DME significantly improves visual acuity and retinal anatomical structure throughout 2 years. The evaluated predictors might help guide routine clinical treatment in DME.
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema. (Pubmed Central) - Dec 16, 2021
The evaluated predictors might help guide routine clinical treatment in DME. Intravitreal anti-VEGF injections in patients with DME were found not to affect corneal parameters, namely ECD, hexagonality, coefficient of variation of the cell size and CCT at the long-term follow-up of 12 months.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Relationship between metamorphopsia and inner retinal microstructure following intravitreal ranibizumab injection for branch retinal vein occlusion. (Pubmed Central) - Dec 16, 2021
Post-treatment metamorphopsia scores were significantly associated with pre-treatment metamorphopsia scores, the extent of DRIL, and the number of injections. Prognostic factor of metamorphopsia was the degree of pre-treatment metamorphopsia.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection. (Pubmed Central) - Dec 16, 2021
Non-infectious IOI following intravitreal anti-VEGF injection typically occurs without pain, conjunctival injection, hypopyon, or fibrin and responds well to topical steroid therapy. Visual acuity returns to baseline levels within weeks according to the severity of inflammation.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Management of retinopathy of prematurity (ROP) in a Polish cohort of infants. (Pubmed Central) - Dec 16, 2021
As the first line of treatment, 115 infants (226 eyes, 64.6%) underwent laser photocoagulation (LP); 61 infants (120 eyes, 34.3%) received intravitreal ranibizumab injections (IVR); and 2 infants (4 eyes, 0.6%) were treated simultaneously with LP and IVR...The incidence of ROP, ROP requiring treatment, and reoccurrence rates are higher in the Polish population than in Western Europe and the USA. The identified treatment patterns find increasing use of anti-VEGF agents.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness. (Pubmed Central) - Dec 16, 2021
Multiple IVR and IVA injections are apparently safe considering peripapillary RNFL damage in patients with exudative AMD. The decreased RNFL thickness of the global sector was presumably due to anatomical improvement of macular lesions.
- || LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy. (Pubmed Central) - Dec 16, 2021
Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.
- || Avastin (bevacizumab) / Roche
Review, Journal: Screening for retinopathy of prematurity-the most important changes in the new German guidelines 2020 (Pubmed Central) - Dec 16, 2021
The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment. The guideline recommendations enable a reliable identification of infants at risk for ROP for screening inclusion and a timely detection of advanced disease stages for treatment initiation, thus preventing blindness from ROP.
- | LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
Journal: Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina. (Pubmed Central) - Dec 16, 2021
Repeated anti-VEGF injections in nAMD appear to have no significant effect on the RNFL, GCL, IPL, and INL thicknesses of the lesion-free retina. Additionally, there was no significant difference in inner retinal layer changes between in eyes treated with anti-VEGF injections for nAMD and fellow eye group during 1-year follow-up.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization. (Pubmed Central) - Dec 16, 2021
Angiogenic, growth factors and inflammatory are involved in the formation of neovascularization of AMD patients. IVR did not cause significant differences in any growth factors or inflammatory cytokines in nAMD patients with the exception of VEGF.
- | Avastin (bevacizumab) / Roche
Journal: The Eye in Internal Medicine: Diabetic retinopathy (Pubmed Central) - Dec 16, 2021
The same accounts for the collaboration of opthalmologists, general practioners, and diabetologists. Good control of diabetes and blood pressure is still important.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study. (Pubmed Central) - Dec 16, 2021
P=N/A
Good control of diabetes and blood pressure is still important. PIR + IVR or PRP + IVR are comparable strategies regarding FLA control in PDR and led to similar retinal function impairment, based on ERG changes up to one-year follow-up.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab. (Pubmed Central) - Dec 16, 2021
In eyes of patients with non-high-risk proliferative diabetic retinopathy, panretinal photocoagulation treatment with ranibizumab appears to cause less damage to contrast sensitivity compared with panretinal photocoagulation treatment alone. Thus, our evaluation of contrast sensitivity may support the use of ranabizumab as an adjuvant to panretinal photocoagulation for the treatment of proliferative diabetic retinopathy.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Outcomes of combined treatments in patients with retinal arterial macroaneurysm. (Pubmed Central) - Dec 16, 2021
To evaluate the outcome of the combined approach between intravitreal ranibizumab (IVR) and focal laser photocoagulation (FLP) in the treatment of symptomatic retinal arterial macroaneurysm (RAM)...No ocular and/or systemic side effects were evident, and no recrudescence of RAM was seen within the 6 months of follow-up. The combined treatment of IVRs and FLPs was successful in the management of symptomatic RAM.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Retinal Vein Occlusion Following Two Doses of mRNA-1237 (Moderna) Immunization for SARS-Cov-2: A Case Report. (Pubmed Central) - Dec 13, 2021
We report a case with retinal vein occlusion 48 hours after vaccination with the SARS-Cov-2 mRNA-1237 vaccine; however, the relationship between these two events remains unclear. Further research is warranted to better understand the potential link between retinal thrombotic events and vaccination.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: A Novel Approach for Development of Intraocular Biodegradable Ranibizumab Implant: A Solution for Stability of Protein Activity. (Pubmed Central) - Dec 13, 2021
In this study, for the first time, we proposed a method for developing a sustained-release intraocular implant, consisting of ranibizumab by the heating method. This method allows for the industrial production of ranibizumab by extrusion and eliminates the complications related to reservoir systems.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: REBEL: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema (clinicaltrials.gov) - Dec 9, 2021
P4, N=56, Recruiting, Sponsor: Cairo University
This method allows for the industrial production of ranibizumab by extrusion and eliminates the complications related to reservoir systems. Not yet recruiting --> Recruiting
- ||||| vamikibart (RG6179) / Roche
New P2 trial: A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (clinicaltrials.gov) - Dec 9, 2021
P2, N=320, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| vamikibart (RG6179) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P2 trial, Combination therapy: A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema (clinicaltrials.gov) - Dec 9, 2021
P2, N=160, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Treatment patterns and outcomes with antivascular endothelial growth factor agents for wet age-related macular degeneration in clinical practice: an analysis of the IRIS Registry. (Pubmed Central) - Dec 7, 2021
By the end of year 3, more than one-third of eyes had discontinued treatment. Given the high treatment burden, wet AMD patients may benefit from more durable approaches that require less frequent dosing.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Microvascular Structure Changes After Intravitreal Ranibizumab Injection in Retinal Vein Occlusion Patients With and Without Macular Ischemia. (Pubmed Central) - Dec 7, 2021
At the same time, some patients with macular ischemia presented reperfusion in macular nonperfusion areas, and still a few patients presented aggravated macular ischemia. Macular ISI is a good way to evaluate macular perfusion status in RVO compared to VD.
- |||||| Lucentis (ranibizumab) / Roche, Novartis
New trial, Adverse events, HEOR, Real-world evidence, Real-world: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) (clinicaltrials.gov) - Dec 6, 2021
P=N/A, N=369600, Completed, Sponsor: Novartis Pharmaceuticals
- || Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: Efficacy and Safety of Various Treatments for Proliferative Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Dec 5, 2021
In addition, our analysis of complications also showed that the overall incidence of adverse reactions of PRP (11.1 ± 12.4, %) was greater than that of ranibizumab (10.6 ± 13.0, %). However, more high-quality randomized controlled trials with longer follow-up using standard methods are still needed to verify the correlation.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: INTRAOCULAR JARISCH-HERXHEIMER REACTION IN LEMIERRE SYNDROME. (Pubmed Central) - Dec 2, 2021
However, more high-quality randomized controlled trials with longer follow-up using standard methods are still needed to verify the correlation. To the best of our knowledge, this is the first reported case of an isolated intraocular Jarisch-Herxheimer reaction induced by Lemierre syndrome antibiotherapy and successfully treated with a single intravitreal injection of ranibizumab.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, P4 data, Journal: Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. (Pubmed Central) - Dec 2, 2021
To the best of our knowledge, this is the first reported case of an isolated intraocular Jarisch-Herxheimer reaction induced by Lemierre syndrome antibiotherapy and successfully treated with a single intravitreal injection of ranibizumab. The study results support the use of either ranibizumab monthly or PRN regimens in Chinese patients with nAMD, regardless of presence of PCV.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Choroidal Detachment following an Intravitreal Injection in a Patient with Vogt-Koyanagi- Harada Disease. (Pubmed Central) - Dec 1, 2021
The subretinal fluid and cystic spaces due toCNVM also resolved completely. This is the first report of a patient with VKH disease developing choroidal detachment following an uncomplicated intravitreal injection of ranibizumab for an inflammatory CNVM.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Comparison of Ranibizumab versus Aflibercept in Treating Macular Edema among Patients with Serous Retinal Detachment Secondary to Branch Retinal Vein Occlusion. (Pubmed Central) - Dec 1, 2021
Those differences disappeared in the subsequent 9 months, and changes in CFT, BCVA, and height of SRD were similar between groups at all other visits. Aflibercept was more effective than ranibizumab from baseline to Month 3 in ME with SRD following BRVO.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Effectiveness and Safety of Coadministration of Intravitreal Dexamethasone Implant and Silicone Oil Endotamponade for Proliferative Diabetic Retinopathy with Tractional Diabetic Macular Edema. (Pubmed Central) - Dec 1, 2021
In the postoperative period, the DME development rate and intravitreal ranibizumab (IVR) injection requirement were significantly higher in Group 1 (P > 0.05). Coadministration of IVD implant and silicone oil endotamponade to the eyes with PDR during vitrectomy seems to be safe and effective application and may decrease the rate of DME and the requirement of IVR injection.
- | Avastin (bevacizumab) / Roche
Journal: Anti-VEGF Therapy in Myopic CNV. (Pubmed Central) - Dec 1, 2021
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended as the first-line treatment option for mCNV. Prompt treatment of active mCNV with intravitreal anti-VEGF therapy has been demonstrated effective in terms of visual outcome improvements reducing the occurrence of late-stage complications.
- ||| Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche
Review, Journal, Adverse events: Side Effects of Brolucizumab. (Pubmed Central) - Nov 30, 2021
A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.
- || Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: RAZORBILL: A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (clinicaltrials.gov) - Nov 29, 2021
P=N/A, N=720, Recruiting, Sponsor: Novartis Pharmaceuticals
In the present article, we have reviewed the reported side effects of brolucizumab. Trial completion date: Aug 2022 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2023
- | Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation (clinicaltrials.gov) - Nov 29, 2021
P3, N=60, Not yet recruiting, Sponsor: Affiliated Hospital of Nantong University
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy. (Pubmed Central) - Nov 29, 2021
This study suggests that TGF-β, ICAM-1, IL-10, VEGF, and VCAM-1 may play a role in the progression of diabetic retinopathy, especially TGF-β, which may plays a significant role in NVG-PDR. These cytokines potentially may be used as biomarkers to predict the progress of diabetic retinopathy, contribute to the choice of treatment options and/or monitor treatment responses.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal: Clinical Outcomes of Eyes With Diabetic Macular Edema Switched From Aflibercept to Ranibizumab Therapy. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2020;51:691-697.].
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Impact of Delayed Time to Treatment on Visual Outcomes in Neovascular AMD: Data From the HARBOR Study. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2021;52:62-69.].
- || Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR, Real-world evidence: Real-World Treatment Patterns in a Population With Neovascular AMD Treated With Anti-VEGF Agents. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2021;52:190-198.].
- | Avastin (bevacizumab) / Roche
Journal: Racial Differences in Anti-VEGF Intravitreal Injections Among Commercially Insured Beneficiaries. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2021;52:208-217.].
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Anti-VEGF Treatment Patterns in Patients With Wet Age-Related Macular Degeneration in Clinical Practice. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2021;52:263-272.].
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Real Life Data of Treat And Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age Related Macular Degeneration Patients: 3 Year Results. (Pubmed Central) - Nov 29, 2021
In addition, BCVA demonstrated an increase of 4.1±0.44 letters in IVR group and 4.36±0.67 letters in IVA group after 36 months compared to the baseline (p>0.05). Both IVR and IVA injections provided significant improvements and stability in BCVA and CMT, however there was no significant difference between IVR and IVA injections with TE protocol of 36 months.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Rates of Suspected Endophthalmitis Following Intravitreal Injections in Clinical Practices in the United States. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2021;52:312-318.].
- | Avastin (bevacizumab) / Roche
Journal: Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral Center. (Pubmed Central) - Nov 29, 2021
[Ophthalmic Surg Lasers Imaging Retina. 2021;52:319-326.].
- | Avastin (bevacizumab) / Roche
Journal: Incidence of Newly Registered Blindness From Age-Related Macular Degeneration in Australia Over a 21-Year Period: 1996-2016. (Pubmed Central) - Nov 29, 2021
The increase in new blindness registrations due to AMD coincided with public funding of verteporfin for PDT, whereas the subsequent decline occurred when bevacizumab was used off-label and ranibizumab and aflibercept were publicly funded. An understanding of the effect of retinal therapy on public health measures may inform improvements in the allocation of limited resources.
- || fluocinolone acetonide / Generic mfg.
Clinical data, Retrospective data, Journal: Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy. (Pubmed Central) - Nov 29, 2021
Results confirm that Ranibizumab, Aflibercept, and Dexamethasone implant are effective and safe in DME treatment. A switch to Dexamethasone implant for patients receiving Aflibercept or Ranibizumab with minimal/no clinical benefit should be considered.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients. (Pubmed Central) - Nov 29, 2021
We also included genetic variants in the VEGFA gene. Based on our results, ARMS2 (rs10490924) and CFH (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included VEGFA genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.